Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984087 | 0.85 | MAPK1 (0.50) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL66188 | 0.84 | TSHR (0.70) | LMNATSHRMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15071602 | 0.84 | TSHR (0.70) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL7412893 | 0.82 | SMN1; SMN2 (0.67) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL8262950 | 0.81 | PTGS1 (0.61) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL10497671 | 0.81 | LMNA (0.62) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL5012595 | 0.81 | SMN1; SMN2 (0.59) | LMNATSHRMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2618025 | 0.81 | LMNA (0.59) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL1178903 | 0.81 | PTGS2 (0.53) | LMNATSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL1949836 | 0.80 | HTT (0.57) | LMNATSHRALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-08-19 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-12-05 | — | — | US | disclosed |
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-3472165-B1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2023-09-06 | — | — | EP | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003072577-A1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1183245-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1183245-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6218408-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| WO-2000064880-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| EP-0466096-A1 | Derivatives of 4-hydroxyphenylsulfone | JUJO PAPER CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | LMNA 2428/4885TSHR 1115/4885MAPK1 843/4885 |
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | NFE2L2, KEAP1, NFE2 | LMNA 1777/4885TSHR 3644/4885MAPK1 1691/4885 |
| US-11833153-B2 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | ATF4, MAP3K1, MAP3K6 | LMNA 1936/4885TSHR 4244/4885MAPK1 32/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | LMNA 3603/4885TSHR 1868/4885MAPK1 478/4885 |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | LMNA 3981/4885TSHR 13/4885MAPK1 1075/4885 |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | LMNA 2974/4885TSHR 89/4885MAPK1 2814/4885 |
| US-20030232994-A1 | Bicyclic thiophene derivatives and combinatorial libraries thereof | CXCR2, BICRA, CXCR1 | LMNA 4767/4885TSHR 771/4885MAPK1 2548/4885 |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | LMNA 2999/4885TSHR 3998/4885MAPK1 3510/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | LMNA 770/4885TSHR 3754/4885MAPK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.